EC Number   |
Application |
Reference |
|---|
   3.4.23.15 | diagnostics |
comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass, the ratio of plasma renin activity to plasma aldosterone concentration is a screening test for primary hyperaldosteronism |
668473 |
| 3.4.23.15 | diagnostics |
the plasma aldosterone-to-renin ratio measuring plasma renin activity, PRA, is used for screening of primary aldosteronism |
669705 |
| 3.4.23.15 | diagnostics |
the ratio of plasma aldosterone concentration to plasma renin activity is used for screening for primary aldosteronism in hypertension, development of a test method, overview |
668286 |
| 3.4.23.15 | medicine |
blockade of renin activation is a therapeutic target to prevent glomerular injury and associated proteinuria |
710823 |
| 3.4.23.15 | medicine |
depending on incubation conditions, circulating renin inhibitors interfere with the recognition of active renin molecules by the monoclonal antibodies used in commercial available assays. Careful considerations must therefore by given to the methodology used for quantifying immunoreactive plasma active renin when patients are treated with renin inhibitors, to avoid an overestimation of the magnitude of active renin release attributable to conformational changes in plasma prorenin |
681186 |
| 3.4.23.15 | medicine |
direct renin inhibition with aliskiren represents an effective option for the long-term treatment of essential hypertension |
711766 |
| 3.4.23.15 | medicine |
hypertension is a pathophysiologically heterogeneous condition in which renin-angiotensin system activity is an important determinant of the blood pressure response to antihypertensive drug treatment. The pretreatment plasma renin activity level is a significant predictor of treatment efficacy despite the different experimental designs employed and the ethnically diverse populations evaluated. These observations support the case that pathophysiologic markers such as plasma renin activity should be incorporated into the design of studies that assess antihypertensive treatment strategies |
677442 |
| 3.4.23.15 | medicine |
in patients with biopsy-confirmed post-transplant glomerulonephritis, statins and renal reini-angiotensin system blockers prolong graft survival. The effect persists after adjustment for presentation with nephrotic syndrome, graft dysfunction, mean arterial pressure, immunosuppression enhancement with mycophenolate mofetil |
695614 |
| 3.4.23.15 | medicine |
inhibition of the renin-angiotensin-aldosterone system plays a pivotal role in preventing and treating diabetic nephropathy. Inhibition of renin with aliskiren decreases blood pressure in patients with hypertension. Direct renin inhibition with aliskiren has antiproteinuric effects in type 2 diabetic patients with nephropathy and additive proteinuric effects when used in diabetic patients already treated with the maximal dose of angiotensin type 1 receptor blockers |
711793 |
| 3.4.23.15 | medicine |
plasma active renin concentration is superior to plasma renin activity and a high plasma active renin concentration is an independent prognostic predictor in heart failure patients who are already receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers |
679245 |
